{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Chris+Green&AnsweringBody.=Department+of+Health+and+Social+Care&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMember.label=Biography+information+for+Chris+Green&AnsweringBody.=Department+of+Health+and+Social+Care&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Chris+Green&AnsweringBody.=Department+of+Health+and+Social+Care&_metadata=all&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Chris+Green&_page=0&AnsweringBody.=Department+of+Health+and+Social+Care&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Chris+Green&AnsweringBody.=Department+of+Health+and+Social+Care&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography+information+for+Chris+Green&AnsweringBody.=Department+of+Health+and+Social+Care&hansardHeading=National+Institute+for+Health+and+Care+Excellence", "items" : [{"_about" : "http://data.parliament.uk/resources/1416468", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1416468/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) has rescheduled one appraisal of an oncology technology in the last six months for operational reasons. NICE\u2019s appraisal of pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer has been delayed by approximately three months due to the volume of topics in its work programme. NICE\u2019s final guidance is expected to be published in November 2022.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2022-01-31", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-01-31T17:57:59.237Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-01-25", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 January 2022 to Question 96910 on National Institute for Health and Care Excellence, how many oncology technical appraisals have been rescheduled in the last six months directly as a result of NICE operational challenges; and what the average time taken has been to reschedule those appraisals.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "111625"}
    , {"_about" : "http://data.parliament.uk/resources/1399150", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1399150/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is committed to publishing draft recommendations on new medicines around the time of licensing, with final guidance within three months of licensing wherever possible. The Department holds regular accountability meetings with NICE on a range of topics, including capacity issues. NICE delivers timely guidance on new medicines in the vast majority of cases and expects to continue to do so.<\/p><p>Project Orbis has been established to allow participating partners, including the United Kingdom, to review and approve applications for promising cancer treatments efficiently. The Medicines and Healthcare products Regulatory Agency, NICE and NHS England and NHS Improvement are ensuring an integrated, timely approach to access new products, including those licensed through Project Orbis. NHS England and NHS Improvement and NICE have agreed principles to allow potential interim access ahead of NICE\u2019s guidance where timely guidance is not anticipated, which has supported early patient access for a number of medicines licensed through Project Orbis.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2022-01-11", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "96909"}
        , {"_value" : "96910"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-01-11T09:29:32.533Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-01-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE on their (a) current and (b) future capacity to deliver final draft guidance on medicines within three months of regulatory approval by the MHRA.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "96908"}
    , {"_about" : "http://data.parliament.uk/resources/1399156", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1399156/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is committed to publishing draft recommendations on new medicines around the time of licensing, with final guidance within three months of licensing wherever possible. The Department holds regular accountability meetings with NICE on a range of topics, including capacity issues. NICE delivers timely guidance on new medicines in the vast majority of cases and expects to continue to do so.<\/p><p>Project Orbis has been established to allow participating partners, including the United Kingdom, to review and approve applications for promising cancer treatments efficiently. The Medicines and Healthcare products Regulatory Agency, NICE and NHS England and NHS Improvement are ensuring an integrated, timely approach to access new products, including those licensed through Project Orbis. NHS England and NHS Improvement and NICE have agreed principles to allow potential interim access ahead of NICE\u2019s guidance where timely guidance is not anticipated, which has supported early patient access for a number of medicines licensed through Project Orbis.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2022-01-11", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "96908"}
        , {"_value" : "96909"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-01-11T09:29:32.66Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-01-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the impact of operational challenges faced by NICE on its ability to deliver timely patient access to new medicines.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "96910"}
    , {"_about" : "http://data.parliament.uk/resources/1385862", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1385862/answer", "answerText" : {"_value" : "<p>Departmental officials regularly discuss a range of issues with the National Institute for Health and Care Excellence (NICE), including the ongoing methods and process review.<\/p><p>NICE recommends the vast majority of medicines it appraises. It has consulted on proposed changes to its methods and processes which will ensure it retains global leadership in the evaluation of new medicines and technologies and provides more equitable access for patients with severe diseases. NICE has undertaken analysis of the impact of its proposed methods in developing the proposals.<\/p><p>NICE is proposing a number of changes to ensure its methods and process are fairer, more consistent and accelerate the introduction of emerging new types of technology. This will support the Life Sciences Vision\u2019s commitment to make the United Kingdom the best place in the world to develop, trial, launch and adopt innovative new medicines, improving patient access to medicines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2021-12-15", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "88743"}
        , {"_value" : "88745"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-12-15T17:02:13.447Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-12-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the NICE Methods Review, if he will hold discussions with NICE in the event that its new methods for appraising medicines impact on the number of patients receiving access to promising treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "88744"}
    , {"_about" : "http://data.parliament.uk/resources/1385863", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1385863/answer", "answerText" : {"_value" : "<p>Departmental officials regularly discuss a range of issues with the National Institute for Health and Care Excellence (NICE), including the ongoing methods and process review.<\/p><p>NICE recommends the vast majority of medicines it appraises. It has consulted on proposed changes to its methods and processes which will ensure it retains global leadership in the evaluation of new medicines and technologies and provides more equitable access for patients with severe diseases. NICE has undertaken analysis of the impact of its proposed methods in developing the proposals.<\/p><p>NICE is proposing a number of changes to ensure its methods and process are fairer, more consistent and accelerate the introduction of emerging new types of technology. This will support the Life Sciences Vision\u2019s commitment to make the United Kingdom the best place in the world to develop, trial, launch and adopt innovative new medicines, improving patient access to medicines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2021-12-15", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "88743"}
        , {"_value" : "88744"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-12-15T17:02:13.493Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-12-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will hold discussions with NICE on ensuring that their Methods Review achieves the Government's commitment for life sciences as set out in the Life Sciences Vision, published in July 2021.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4398", "label" : {"_value" : "Biography information for Chris Green"}
      }
      , "tablingMemberConstituency" : {"_value" : "Bolton West"}
      , "tablingMemberPrinted" : [{"_value" : "Chris Green"}
      ], "uin" : "88745"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 5, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}